UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 1, 2017 (February 27, 2017)
BioDelivery Sciences International, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-31361 | | 35-2089858 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
4131 ParkLake Ave., Suite #225 Raleigh, NC | | 27612 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including areacode: 919-582-9050
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
This Amendment No. 1 toForm 8-K (this“Form 8-K/A”) amends the Current Report on Form8-K (the “Form8-K”) originally filed by BioDelivery Sciences International, Inc. (the “Company”) with the Securities and Exchange Commission on February 27, 2017.
The sole purpose of this Form8-K/A is to file as a replacement exhibit to the8-K an updated redacted version of the Term Loan Agreement (the “Loan Agreement”) by and among the Company and the Company’s wholly-owned subsidiaries, on the one hand, and CRG Servicing LLC, on the other hand. The remainder of the Form8-K remains unchanged.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| * | Confidential treatment is requested for certain portions of this exhibit pursuant to 17 C.F.R. Sections 200.8(b)(4)and 240.24b-2. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | |
| | | | BIODELIVERY SCIENCES INTERNATIONAL, INC. |
| | | |
| Dated: September 1, 2017 | | | | By: | | /s/ Ernest R. De Paolantonio |
| | | | | | Name: Ernest R. De Paolantonio |
| | | | | | Title: Chief Financial Officer, Treasurer and Secretary |
